文献速递头颈甲状腺与浅表介入

微波消融与手术切除治疗原发性甲状旁腺功能亢进的长期结局及预后因素

Long-term outcomes and prognostic factors following microwave ablation vs surgical resection for primary hyperparathyroidism.
PubMed 文献 · Eur Radiol · 2026-01-05

本回顾性研究纳入172例原发性甲状旁腺功能亢进患者,88例接受微波消融、84例接受手术切除,中位随访分别为70.7和77.7个月。结果显示两组总体及1、3、5年长期缓解率无显著差异,5年缓解率分别为77.2%与83.1%,log-rank p=0.78。单个甲状旁腺结节与更高治愈率相关,血肌酐升高与缓解丧失相关。

要点

  • 5年长期缓解率在微波消融组与手术切除组间无统计学差异(77.2% vs 83.1%,p=0.78)。
  • 治疗前发现单个甲状旁腺结节提示治愈机会更高(OR 3.70,p=0.048)。
  • 血肌酐较高者长期缓解丧失风险增加(HR 1.05,p=0.02),报告时需关注肾功能。

核心结论

  • 微波消融治疗原发性甲状旁腺功能亢进的5年长期缓解率为77.2%,与手术切除83.1%无统计学差异(log-rank p=0.78)。
  • 单个甲状旁腺结节和肾功能正常与更好的结局相关,与治疗方式无关。

研究设计与样本

  • 回顾性研究,纳入2015年至2025年172例原发性甲状旁腺功能亢进患者。
  • 88例接受微波消融,84例接受手术切除;微波消融组中位随访70.7个月(IQR 42.6-96.3),手术组77.7个月(IQR 56.5-113.8)。
  • 结局指标包括首次治疗成功率、治愈率和长期缓解率,并采用多变量回归校正基线变量。

诊断标准与关键数值

  • 首次治疗成功定义为单次手术后生化正常且无需额外干预。
  • 5年长期缓解率:微波消融77.2%,手术切除83.1%,log-rank p=0.78。
  • 治疗方式与治愈率无关:校正后OR 1.92(95%CI 0.59-6.28,p=0.28)。
  • 单个甲状旁腺结节预测治愈:OR 3.70(95%CI 1.02-3.49,p=0.048)。
  • 血肌酐较高预测长期缓解丧失:HR 1.05(95%CI 1.01-1.09,p=0.02)。

临床应用与阅片要点

  • 微波消融可作为部分原发性甲状旁腺功能亢进患者的微创替代方案,需结合结节数目与肾功能选择。
  • 消融前影像发现单个甲状旁腺结节提示治愈机会较高,报告中应明确结节数目。
  • 血肌酐升高患者消融后长期缓解可能下降,随访中需更密切监测。
  • 两组并发症率相似(6.8% vs 3.6%,p=0.30),但仍需关注操作相关并发症。

局限性

  • 回顾性研究设计存在选择偏倚和混杂可能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To compare the long-term efficacy and safety of microwave ablation (MWA) vs surgical resection (SR) in patients with primary hyperparathyroidism (PHPT) over five years.

MATERIALS AND METHODS: This retrospective study evaluated 172 consecutive patients with PHPT (88 underwent MWA, 84 underwent SR) from 2015 to 2025. The median follow-up was 70.7 months (interquartile range [IQR], 42.6-96.3) in the MWA group and 77.7 months (IQR, 56.5-113.8) in the SR group. Primary outcomes included first-treatment success rate (biochemical normalization after a single procedure without additional interventions), cure rate, and long-term remission rate. Clinical, laboratory, and imaging parameters were analyzed to identify prognostic indicators. Multivariable regression adjusted for key baseline variables.

RESULTS: No significant differences were observed in overall or 1-, 3-, and 5-year long-term remission rates (all p > 0.05) between MWA and SR groups (5-year rate, 77.2% vs 83.1%, log-rank p = 0.78). After adjustment, treatment modality was not associated with cure rate (odds ratio [OR], 1.92; 95% confidence interval [CI], 0.59-6.28; p = 0.28) or long-term remission (hazard ratio [HR], 0.79; 95% CI: 0.18-3.53; p = 0.75). A single parathyroid nodule predicted cure (OR, 3.70; 95% CI: 1.02-3.49; p = 0.048), while higher serum creatinine predicted remission loss (HR, 1.05; 95% CI: 1.01-1.09; p = 0.02). Complication rates were comparable between groups (6.8% vs 3.6%, p = 0.30).

CONCLUSION: MWA provides long-term efficacy comparable to SR for PHPT over five years. Solitary parathyroid nodules and normal renal function are associated with better outcomes regardless of treatment modality.

KEY POINTS: Question Can MWA achieve long-term efficacy and safety comparable to SR in patients with PHPT? Findings Five-year remission was similar between MWA and SR = 0.78); major complication rates also did not differ. Solitary nodules predicted cure, while elevated creatinine was linked to remission loss. Clinical relevance MWA offers a minimally invasive alternative to SR in selected patients with PHPT, providing comparable five-year biochemical remission with a similar safety profile.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Wei, Zhao, Wu, et al. Long-term outcomes and prognostic factors following microwave ablation vs surgical resection for primary hyperparathyroidism. Eur Radiol. 2026. PMID: 41492024. doi:10.1007/s00330-025-12254-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。